We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Volume over the last few weeks is abnormally high, not only in Aug, but also this month Sep already nearly 3x more volume than normal. And we still have two weeks left of Sep... I expect RNS this week with interims and update on new strategy and US sales.
Cheers
63% free float according to ft
Anyone know the feee float and what a likely takeover sp?
Hemodynamic Monitoring Devices Market Worth $1.4 Billion By 2024
May 2016
https://www.grandviewresearch.com/press-release/global-hemodynamic-monitoring-devices-market
I especially like the following part: "“The TrueVue platform now enables Deltex Medical to market its haemodynamic monitoring technologies into a SIGNIFICANTLY BROADER NUMBER of CLINICAL AREAS in the UK including accident & emergency, awake-surgery and obstetrics.”
The TrueVue platform could potentially open up whole new areas of the haemodynamic/ODM market not only everywhere in the UK but also elsewhere.
Investors in oesophageal doppler monitoring technology company Deltex Medical Group heard how its technology was solving problems increasingly faced by hospitals on Wednesday, as they gathered for its annual general meeting.
The AIM-traded firm said hospitals in the developed world were facing “increasing pressure” to focus on patient safety, in part due to financial penalties or the non-reimbursement of costs associated with avoidable adverse events.
Chairman Nigel Keen said healthcare systems also faced increasing costs from ageing populations.
Avoidable haemodynamic complications - such as surgical site infections or acute kidney injuries - were expensive, Keen explained, and caused significant patient safety issues.
“Deltex Medical's ODM technology has been shown in numerous scientific studies to improve patient outcomes; reduce attributable costs; and by extension, improve patient safety,” he said.
“For example, the April 2018 FEDORA study showed a statistically significant reduction in complications and median length of stay for high, moderate and low risk patients.”
This year, Keen said Deltex Medical launched its ‘TrueVue’ monitoring platform in the UK, which comprised three haemodynamic monitoring technologies - doppler ultrasound; impedance; and arterial waveform analysis.
“We are waiting for regulatory approval to launch the full suite of TrueVue products in the US.
“In general terms there is a trade-off between the ease-of-use and the precision of the data generated from each monitoring technology,” he explained.
“The TrueVue platform enables clinicians to match the appropriate technology to the risk profile of the patients as they move through the hospital.”
Nigel Keen said that for example, high-risk, anaesthetised patients undergoing surgery could be treated under the guidance of the minimally-invasive and very precise ODM probe, whereas lower-risk, awake patients in a high dependency unit could be monitored using non-invasive impedance.
The TrueVue platform also enabled the Group to sell its monitoring technologies into a larger addressable market, he added.
“In the past, Deltex Medical was only able to provide its ODM technology to anaesthetists for use on anaesthetised patients undergoing surgery in the operating theatre or sedated patients in an intensive care unit.
“The TrueVue platform now enables Deltex Medical to market its haemodynamic monitoring technologies into a significantly broader number of clinical areas in the UK including accident & emergency, awake-surgery and obstetrics.”
Andy Mears, the firm’s new CEO, started with Deltex Medical as an electrical engineer working on the first prototypes of the ODM technology in 1989, Keen said.
“He has extensive practical experience of working with the ODM technology as well as discussing its development and application with clinicians working in operating theatres and intensive care.
“In his previous role he was responsible for
2 Million additional cash, 1 Million annual cost reduction, expanding growth through TrueVue platform, recent major contracts in US and 4 MM contract in France, more major US hospitals to follow shortly in H218 and director recently buying millions of shares adding up to 54 Million... make that of what you will.
Did you catch takeover gos and isnit just that. I haven’t seen a stock on AIM with director deals for a long long time. That’s what attracted me more so.
no worries dealer
It would be more helpful to newcomers to Deltex if you simply drew their attention to the relevant RNSs complete with dates. Youcould have put --- please read the followihg RNS:-
October 2017 regarding major hospital system in USA. (Comprising 13 hospitals)
January 2018 regarding major hospital system in USA. (Comprising 6 hospitals) ------ Yours, Max.
Ps. Didn’t mean that in a harsh way, good luck all here for the same thing, this ones intriguing.
Good news but I’d value opinions over posts of info already in the domain. Cheers
More news coming soon:..... "The flagship hospital has now started implementing ODM into its standard operating procedures for both colorectal and urological surgery. The clinicians leading the implementation programme have informed the Company that they expect this to lead to use of 40 to 50 probes a month; furthermore, that the system plans to introduce ODM into the two largest sister hospitals in Q2 2018 and the remaining three hospitals by Q4 2018 by which time the flagship hospital expects to have started to roll ODM usage out into other surgical disciplines. The Company is supporting the implementation from its existing resources with no additional overhead."
Some mention of a takeover, was that pure guesswork or some meat on the bone ?
The interims will this time also surely include the results of the major new hospital in the USA since Jan this year. "The hospital is a University Teaching Hospital in our Mid-Atlantic sales territory and the flagship site within a six hospital healthcare system. It is ranked amongst the top ten hospitals in the USA." "This is a strategically important account win for Deltex in an important teaching hospital. Successful implementation through the hospital and wider system should help drive our overall US sales growth as well as providing an additional highly rated reference account. "The results from the hospital's evaluation validate the value our ODM technology offers even in those hospitals that have the very best patient outcomes. It is noteworthy that this US hospital was able to use ODM to improve its patients' recoveries even though its starting points for lengths of stay for these types of surgery were already around half the NHS England average."
Unlikely to be this week sir
Could be next week
TrueVue kicking off since introduction last year... "We have seen a number of new accounts coming on stream in the US market, including a very major one which started using TrueVueTM Doppler as the result of a rigorous and successful evaluation. Our French distributor has been awarded the largest tender which we have seen to date for the use of TrueVueTMDoppler and we have continued to migrate our business towards our multi-modal TrueVueTM System. The TrueVueTM System allows us to refresh our market positioning and through the TrueVueTM System we have the possibility of guidin"g treatment for greater numbers of patients. "In the meantime, the largest ever randomised trial of our core TrueVueTM Doppler technology has been published with excellent results and very broad applicability for patients undergoing surgery who need to be protected from expensive, life-shortening complications. This is further compelling evidence that many of these complications are avoided through the use of TrueVueTMDoppler."
1.50p again... someone's hoovering up these shares continuously it seems like yesterday afternoon... bodes well for Monday
Last sells 1.419p............most are very small, fag money...a rumble in the jungle at finish to go into blue for Monday
Think there is a big buy being worked. The sells aren't moving the price at all!
Will see if something pops up later
Final push sell 1.149 buy 1.48
yes sir troajan momentum building
Let’s see but a strong close would be good and bode well.